Bordetella pertussis IgA

Brand

GENWAY

Overview

Intended Use: The Bordetella pertussis IgA-ELISA is intended for the qualitative determination of IgA class antibodies against Bordetella pertussis and Bordetella pertussis toxin in human serum or plasma (citrate). Introduction: Bordetella species are non-spore-forming encapsulated bipolar coccoid (pale-staining) Gram-negative bacilli (about 0. 3-0. 5 μm thick and 1 μm long). The genus consists of the human parasites B. pertussis and B. parapertussis and B. bronchiseptica and B. avium which cause enzootic infections in various wild and domestic animal species. B. pertussis is the classical exciter of pertussis and exists only in ill people; B. parapertussis causes 5-20% of a milder and often clinical unapparent form of pertussis. B. bronchiseptica has seldomly (eg close contact with animals) human pathogenic significance as opportunistic secondary exciter in mixed infections (bronchitis pneumonia wound infection). Pertussis or whooping cough is a bacterial infection of the respiratory system. It is a highly contagious childhood disease which appears seldomly under adults. It is transmitted by respiratory contact. B. pertussis has the ability to stick to the cilia of the epidermal cells of the respiratory system. Fragments of the bacterial cell wall (ExoToxin = tracheal Cytotoxine TCT) inhibit the movement of the cilia in the tracheal mucosa. After an incubation time of one to three weeks the disease runs through three stages (s. table below). The lethality is 0. 6 % and concerns babies in the first six months with more than 70 %. For newborn and premature infants it is higher (1-2%). In Africa beside measle virus B. pertussis is the main reason for high infant mortility. The distribution of the disease is worldwide. Clinical pertussis is followed by natural acquired immunity which is long-lasting but not permanent. In most countries an active vaccination is recommended which leads to 90% protection for three to twelve years. Usually the immunization preparation is combined with diphtheria and tetanus toxoids. The presence of bacterium resp. infection may be identified byMicroscopy: identification on cultures IFSerology: Detection of antibody production by ELISAPrecise diagnosis is needed for effective treatment of patients for isolation of unvaccinated infants at risk and for differentiation of pertussis from atypic diseases and chronic infections. Principles of the assay: The qualitative immunoenzymatic determination of IgA-class antibodies against Bordetella pertussis is based on the ELISA (Enzyme-linked Immunoorbent Assay) technique. Microtiter strip wells are precoated with Bordetella pertussis/toxin antigens to bind corresponding antibodies of the specimen. After washing the wells to remove all unbound sample material horseradish peroxidase (HRP) labelled anti-human IgA conjugate is added. This conjugate binds to the captured Bordetella pertussis/toxin specific antibodies. The immune complex formed by the bound conjugate is visualized by adding tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of Bordetella pertussis/toxin specific IgA antibodies in the specimen. Sulfuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450nm is read using an ELISA microwell plate reader. Storage and Stability: The reagents are stable up to the expiry date stated on the label when stored at 2?8 °C. Limitations of the Test: Bacterial contamination or repeated freeze-thaw cycles of the specimen may affect the absorbance values. Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis should take into consideration clinical history symptomatology as well as serological data. In immunsuppremized patients and newborns serological data only have restricted value. References Wong K. H. and S. K. Skelton. 1989. Preparation of filamentous hemagglutinin from Bordetella pertussis and assay for serum antibodies to filamentous hemagglutinin and pertussis toxin for clinical and public health lab. J. Clin. Microbiol. 27:2805-2810Zackrission G. I. Krantz T. Legergard P. Larsson R. Sekura N. Sigurs J. Taranger and B. Trollfors. 1988. Humoral antibody response to pertussis toxin in patients with clinical pertussisZachrisson G. I. Krantz T. Lagergard P. Larsson R. Sekura NSigurs S. Taranger and B. Trollfors. 1988. Humoral antibody response to pertussis toxin in patient with clinical pertussis measured by an enzyme-linked immunosorbent assay. Eur. J. Clin. Microbiol. 7:149-154Granstrom M. G. Granstrom A. Lindtors 1982. Serologic diagnosis of whooping cough by an enzyme-linked immunsorbent assay using fimbrial hemagglutinin as antigen. J. Infect. Dis. 146:741-745

spezie

other

detection target

Bordetella pertussis IgA

pack size

1x96 assay